VEGFA and ovarian cancer: However, randomised trials of anti-angiogenic VEGF pathway inhibitors (Burger et al, 2011; Perren et al, 2011; Aghajanian et al, 2012; Ledermann et al, 2013; Pujade-Lauraine et al, 2014; Floquet et al, 2015; Pignata et al, 2015) in ovarian cancer have shown that the addition of such agents to and/or following conventional cytotoxic therapy resulted in improved progression-free survival (PFS) and, in the case of ICON7 (Perren et al, 2011; Oza et al, 2015), overall survival.